Radius Health, Inc. News Releases https://ir.radiuspharm.com/ Radius Health, Inc. News Releases en Radius Health to Present at Goldman Sachs 40th Annual Global Healthcare Conference https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-present-goldman-sachs-40th-annual-global WALTHAM, Mass. , June 04, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona , Chief Financial Officer and Joe Kelly , Senior Vice President of Sales and Marketing, will present a corporate update at the Goldman Sachs 40th Annual Global Healthcare Tue, 04 Jun 2019 09:00:00 -0400 Radius Health, Inc. News Releases 12536 Radius Health to Present at Bank of America Merrill Lynch Health Care Conference 2019 https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-present-bank-america-merrill-lynch-health-care WALTHAM, Mass. , May 10, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona , Chief Financial Officer and Joe Kelly , Senior Vice President of Sales and Marketing, will present a corporate update at the Bank of America Merrill Lynch Health Care Conference Fri, 10 May 2019 16:42:00 -0400 Radius Health, Inc. News Releases 12521 Radius Health Announces First Quarter 2019 Operating Results https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-announces-first-quarter-2019-operating-results TYMLOS® U.S. net sales were $29.8 million in the first quarter of 201 9 doubling over the first quarter of 2018. TYMLOS continued increasing its share in the U.S. anabolic osteoporosis market capturing an average of 30% total market share and 42% share in new patients in the first quarter of 2019. Wed, 08 May 2019 07:56:00 -0400 Radius Health, Inc. News Releases 12511 Radius Health to Announce First Quarter 2019 Financial Results, Host Conference Call and Live Webcast on Wednesday, May 8, 2019 https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-announce-first-quarter-2019-financial-results-host WALTHAM, Mass. , April 23, 2019 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter 2019 financial results on Wednesday, May 8, 2019 . The Company will host a conference call and live audio webcast at 8:00 a.m. Tue, 23 Apr 2019 09:00:00 -0400 Radius Health, Inc. News Releases 12466 Radius Health to Present Two Posters at AACE 2019 Annual Meeting https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-present-two-posters-aace-2019-annual-meeting WALTHAM, Mass. , April 17, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it Wed, 17 Apr 2019 08:00:00 -0400 Radius Health, Inc. News Releases 12436 Radius Health Presents Analysis from Phase 3 ACTIVE Trial and Data from Preclinical Studies for TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-presents-analysis-phase-3-active-trial-and-data -Post-hoc analysis suggests abaloparatide may be useful in the treatment of women with postmenopausal osteoporosis and concurrent osteoarthritis, at high risk for fracture- -Preclinical studies provide explanations for the net bone gain observed in the Phase 3 ACTIVE trial in abaloparatide-treated Sat, 23 Mar 2019 12:45:00 -0400 Radius Health, Inc. News Releases 12421 Radius Health to Present Data on TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-present-data-tymlosr-abaloparatide-injection-endo WALTHAM, Mass. , March 18, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it Mon, 18 Mar 2019 08:00:00 -0400 Radius Health, Inc. News Releases 12416 Radius Health to Present at Cowen 39th Annual Healthcare Conference https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-present-cowen-39th-annual-healthcare-conference WALTHAM, Mass. , March 11, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the Cowen 39 th Annual Healthcare Conference on Wednesday, March 13, 2019 . Mon, 11 Mar 2019 12:30:00 -0400 Radius Health, Inc. News Releases 12401 Radius Health to Participate in 2019 Credit Suisse Global Healthcare Conference https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-participate-2019-credit-suisse-global-healthcare WALTHAM, Mass. , March 01, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Company management will be attending and participating in the 2019 Credit Suisse Global Healthcare Conference in London on Tuesday, March 5, 2019 and hosting one-on-one meetings with Fri, 01 Mar 2019 09:00:00 -0500 Radius Health, Inc. News Releases 12391 Radius Health Announces Fourth Quarter and Full-Year 2018 Operating Results https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-announces-fourth-quarter-and-full-year-2018 TYMLOS® U.S. net sales continued to increase, reaching $34.4 million in the fourth quarter of 2018  and totaling $99.2 million for full-year 2018, exceeding the Company’s guidance of $95-98 million . Elacestrant’s Phase 3 study was initiated at the end of 2018 and is open for enrollment. Thu, 28 Feb 2019 16:05:00 -0500 Radius Health, Inc. News Releases 12376